JPWO2019157340A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019157340A5 JPWO2019157340A5 JP2020542273A JP2020542273A JPWO2019157340A5 JP WO2019157340 A5 JPWO2019157340 A5 JP WO2019157340A5 JP 2020542273 A JP2020542273 A JP 2020542273A JP 2020542273 A JP2020542273 A JP 2020542273A JP WO2019157340 A5 JPWO2019157340 A5 JP WO2019157340A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- present
- range
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 102
- 239000000833 heterodimer Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- -1 ethane sulfone Chemical class 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 102000025171 antigen binding proteins Human genes 0.000 claims description 4
- 108091000831 antigen binding proteins Proteins 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 239000013504 Triton X-100 Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 26
- 239000000178 monomer Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023145922A JP2023162437A (ja) | 2018-02-08 | 2023-09-08 | 低ｐＨ医薬抗体製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628267P | 2018-02-08 | 2018-02-08 | |
| US62/628,267 | 2018-02-08 | ||
| US201962799577P | 2019-01-31 | 2019-01-31 | |
| US62/799,577 | 2019-01-31 | ||
| PCT/US2019/017294 WO2019157340A1 (fr) | 2018-02-08 | 2019-02-08 | Formulation d'anticorps pharmaceutique à ph faible |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145922A Division JP2023162437A (ja) | 2018-02-08 | 2023-09-08 | 低ｐＨ医薬抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512881A JP2021512881A (ja) | 2021-05-20 |
| JPWO2019157340A5 true JPWO2019157340A5 (fr) | 2022-02-16 |
| JP7407118B2 JP7407118B2 (ja) | 2023-12-28 |
Family
ID=65576686
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542273A Active JP7407118B2 (ja) | 2018-02-08 | 2019-02-08 | 低ｐＨ医薬抗体製剤 |
| JP2023145922A Pending JP2023162437A (ja) | 2018-02-08 | 2023-09-08 | 低ｐＨ医薬抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145922A Pending JP2023162437A (ja) | 2018-02-08 | 2023-09-08 | 低ｐＨ医薬抗体製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210047407A1 (fr) |
| EP (1) | EP3749363A1 (fr) |
| JP (2) | JP7407118B2 (fr) |
| AU (1) | AU2019216759A1 (fr) |
| CA (1) | CA3089906A1 (fr) |
| MA (1) | MA51747A (fr) |
| MX (1) | MX2020008219A (fr) |
| UY (1) | UY38080A (fr) |
| WO (1) | WO2019157340A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017342560B2 (en) | 2016-10-14 | 2022-03-17 | Xencor, Inc. | IL15/IL15Ralpha heterodimeric Fc-fusion proteins |
| WO2019204665A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Protéines de fusion hétérodimères ciblant pd-1 contenant des protéines de fusion fc d'il-15/il-15ra, domaines de liaison à l'antigène pd-1 et utilisations associées |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| PE20211091A1 (es) * | 2018-07-02 | 2021-06-14 | Amgen Inc | Proteina de union al antigeno anti-steap1 |
| EA202190382A1 (ru) * | 2018-07-31 | 2021-05-17 | Эмджен Инк. | Фармацевтические составы на основе маскированных антител |
| CA3116188A1 (fr) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Proteines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polytherapies faisant intervenir celles-ci |
| EP3897853A1 (fr) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Protéines de fusion fc hétérodimères ciblées contenant les il-15/il-15ra et des domaines de liaison à l'antigène nkg2d |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CA3160162A1 (fr) * | 2019-11-04 | 2021-05-14 | Compugen Ltd. | Polytherapie avec des formulations d'anticorps anti-pvrig et d'anticorps anti-pd-1 |
| IL299242A (en) * | 2020-08-24 | 2023-02-01 | Amgen Inc | A pharmaceutical formulation that includes BITE, a bispecific antibody, and methionine |
| AU2023204767A1 (en) * | 2022-01-10 | 2024-08-29 | Michael Briskin | Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the same |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4396608A (en) * | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1998048032A2 (fr) | 1997-04-21 | 1998-10-29 | Donlar Corporation | ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| AU2003248370A1 (en) | 2002-02-27 | 2003-09-09 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| SG176455A1 (en) | 2003-10-09 | 2011-12-29 | Ambrx Inc | Polymer derivatives |
| JP2007519422A (ja) | 2004-02-02 | 2007-07-19 | アンブレツクス・インコーポレイテツド | 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2007041635A2 (fr) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées |
| AU2007240732B2 (en) * | 2006-04-21 | 2013-07-04 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| TW200826974A (en) * | 2006-09-07 | 2008-07-01 | Kirin Pharma Kk | Stable lyophilized pharmaceutical preparation comprising antibody |
| MX2009006594A (es) * | 2006-12-21 | 2009-08-12 | Amgen Inc | Formulaciones de ph regulado y estables que contienen polipeptidos. |
| EP2569337A1 (fr) * | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Protéines hétérodimériques et leurs procédés de production et de purification |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US8820052B2 (en) | 2012-02-09 | 2014-09-02 | Ford Global Technologies, Llc | Liquid reductant system and method for operation of the liquid reductant system |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP3620473A1 (fr) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Nouvelles protéines hétérodimères |
| EP3587448B1 (fr) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Protéines hétérodimériques |
| EP3699195A3 (fr) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Anticorps bispécifiques se liant à cd38 et cd3 |
| MA41019A (fr) | 2014-11-26 | 2021-05-05 | Xencor Inc | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
| CN104474547A (zh) * | 2015-01-07 | 2015-04-01 | 蓝佳堂生物医药（福建）有限公司 | 一种抗阴道感染免疫球蛋白复合抑菌剂 |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| ITUB20152921A1 (it) | 2015-08-06 | 2017-02-06 | Lino Manfrotto Co S P A | Supporto orientabile per apparecchiature video-fotografiche |
| TWI797073B (zh) * | 2016-01-25 | 2023-04-01 | 德商安美基研究（慕尼黑）公司 | 包含雙特異性抗體建構物之醫藥組合物 |
| CN110352070B (zh) | 2016-06-14 | 2024-09-17 | Xencor股份有限公司 | 双特异性检查点抑制剂抗体 |
-
2019
- 2019-02-08 MX MX2020008219A patent/MX2020008219A/es unknown
- 2019-02-08 MA MA051747A patent/MA51747A/fr unknown
- 2019-02-08 UY UY38080A patent/UY38080A/es unknown
- 2019-02-08 CA CA3089906A patent/CA3089906A1/fr active Pending
- 2019-02-08 EP EP19707948.6A patent/EP3749363A1/fr active Pending
- 2019-02-08 WO PCT/US2019/017294 patent/WO2019157340A1/fr unknown
- 2019-02-08 JP JP2020542273A patent/JP7407118B2/ja active Active
- 2019-02-08 US US16/964,452 patent/US20210047407A1/en active Pending
- 2019-02-08 AU AU2019216759A patent/AU2019216759A1/en active Pending
-
2023
- 2023-09-08 JP JP2023145922A patent/JP2023162437A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| US20200385456A1 (en) | Stable Dual Variable Domain Immunoglobulin Protein Formulations | |
| JP5896471B2 (ja) | 抗体製剤 | |
| JP2009531371A (ja) | 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤 | |
| TW201726167A (zh) | 抗-ｃｄ１９類美登醇（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物抗體於治療ｂ-細胞惡性症狀之用途 | |
| CN110418803A (zh) | 抗rsv单克隆抗体配制品 | |
| US20220040312A1 (en) | Formulations with reduced degradation of polysorbate | |
| JPWO2019157340A5 (fr) | ||
| JP2017512814A (ja) | 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤 | |
| US20210369616A1 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| JP2023501377A (ja) | 高濃度抗ｃ５抗体配合物 | |
| US20220378908A1 (en) | Compositions and methods for minimizing protein loss at low protein concentrations | |
| US20220187398A1 (en) | Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products | |
| CN116688115B (zh) | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 | |
| US20240342083A1 (en) | Anti-pd-1 antibody pharmaceutical composition and use thereof | |
| WO2023151613A1 (fr) | Molécule bispécifique de liaison à l'antigène et son utilisation | |
| WO2023143347A1 (fr) | Composition pharmaceutique comprenant un conjugué anticorps-médicament anti-cd79b et son utilisation | |
| US20230167175A1 (en) | Pharmaceutical formulation | |
| US20230212271A1 (en) | Compositions and methods for linear and conformational site-specific antibodies and methods of making the same | |
| CN116803420A (zh) | 靶向PD-1和TGFβ的双功能蛋白药物组合物及其用途 | |
| JP2022036932A5 (fr) | ||
| TW202417512A (zh) | 含有抗tigit抗體的配製物及其使用方法 | |
| CN117982437A (zh) | 一种靶向冠状病毒的抗体制剂及其应用 | |
| RU2024104838A (ru) | Фармацевтическая композиция на основе антитела против PD-1 и ее применение |